JCO Precision Oncology · 13 Nov 2026
Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial
Panot Sainamthiph-index 3, Meenakshi Somadasan, Leigh Culnane, Elizabeth Andrews, Lauren Brais, Molly Andrews, Gun Ho Jang, Amy Zhang, Julie M. Wilson, Stephanie Ramotar, Anna Dodd, Kimberly J. Perez, Kenneth Yu, Daniel Laheru, Daniel A. King, Grainne M. O'Kane, Steven Gallinger, David Tuveson, Elizabeth M. Jaffee, Jennifer J. Knox, Faiyaz Notta, Andrew J. Aguirre, Brian M. Wolpin, Adam S. Sperling, Harshabad Singhh-index 13
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Purpose Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). Methods Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression. Results CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH. Conclusion CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Harshabad Singh has the highest h-index among the authors (13).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (19)
What it cites, from open citation data, with Crossref's record of each.